Favorable cash repatriation rates and regulatory approvals for major healthcare deals have not brought an expected surge in mega-mergers among large US pharmaceutical companies, according to healthcare investment bankers.
The chief executive of a Canadian drugmaker is suing a noted short seller for libel after the investor criticized the CEO’s tenure at another drug company, which earlier settled charges of accounting fraud.
A Canadian drugmaker with quite the track record for buyouts has struck a far-reaching deal that it says will enhance its M&A strategy. No, it's not serial dealmaker Valeant ($VRX)--but it may have Valeant worried.
Up and Down the Ladder: The Latest Comings and Goings at Sanofi, EMD Serono and…
Valeant Clone Concordia Top Canada Stock as CEO Eyes Deal
Concordia Healthcare to Buy Some Assets of Covis Pharma for $1.2 Billion